![Continuous Low-dose Lenalidomide Found Safe in Multiple Myeloma Trial | Starton's STAR-LLD Maintained Therapeutic Levels in Healthy Volunteers | Myeloma Research News Continuous Low-dose Lenalidomide Found Safe in Multiple Myeloma Trial | Starton's STAR-LLD Maintained Therapeutic Levels in Healthy Volunteers | Myeloma Research News](https://myelomaresearchnews.com/wp-content/uploads/2022/07/thumbs-up.png)
Continuous Low-dose Lenalidomide Found Safe in Multiple Myeloma Trial | Starton's STAR-LLD Maintained Therapeutic Levels in Healthy Volunteers | Myeloma Research News
![Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma | Leukemia Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2011.126/MediaObjects/41375_2011_Article_BFleu2011126_Fig1_HTML.jpg)
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma | Leukemia
![Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma | Siriraj Medical Journal Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma | Siriraj Medical Journal](https://he02.tci-thaijo.org/public/journals/156/cover_issue_17274_en_US.jpg)
Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma | Siriraj Medical Journal
![Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/59c4346b-264a-425c-b6a6-fec8639eccd3/gr1_lrg.gif)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology
![Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/Browse-tumor-types/heme/5mjc_ASH/4/Slide2.jpg)
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
![Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2473952920317420-absf1.jpg)
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect
![Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma | Chinese Medical Journal Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma | Chinese Medical Journal](https://mednexus.org/cms/asset/fbd4d65c-0952-499e-8b6c-a50b32341450/cm9.0000000000001695.png)
Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma | Chinese Medical Journal
Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials | PLOS ONE
![Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma | Blood Cancer Journal Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-021-00485-5/MediaObjects/41408_2021_485_Fig1_HTML.png)
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma | Blood Cancer Journal
![POR | Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers POR | Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers](https://www.por-journal.com/files/Articles/613264/pore-27-613264-HTML/image_m/pore-27-613264-g002.jpg)